Physician

Gayatri Nimmagadda, M.D.

According to 2025 Medicare claims, Gayatri Nimmagadda, M.D. (NPI: 1770550998) practices hematology/oncology in the Baltimore-Columbia-Towson, MD market, with the plurality of this provider's patient population coming from Anne Arundel, MD. This provider's primary affiliated billing organization is CHESAPEAKE ONCOLOGY HEMATOLOGY ASSOC (NPI: 1821065079; TIN: 521480363) and primary practice location at 21061-5805.

Nimmagadda's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,011 traditional Medicare patients, billed 606,890 HCPCS/CPT codes, and received $4,247,296 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 999 prescription claims across 244 beneficiaries totaling $3,880,307 in drug costs, led by Revlimid (Lenalidomide). DME data shows 24 claims. Open Payments data shows 36 records totaling $987. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,324,689 to $4,247,296. Similarly, Part D prescription costs have moved sharply higher in recent years, from $666,709 to $3,880,307. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $8,795 to $4,918.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	636	298,402	$2,324,689
2016	662	303,731	$2,685,855
2017	673	395,746	$3,252,534
2018	722	418,389	$4,135,446
2019	707	393,168	$3,499,571
2020	813	442,925	$3,854,628
2021	890	584,405	$5,849,207
2022	837	561,416	$5,741,798
2023	948	488,036	$4,945,628
2024	1,011	606,890	$4,247,296

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	140	624	$666,709
2016	154	743	$882,189
2017	186	918	$868,373
2018	199	1,012	$1,504,101
2019	186	945	$1,828,295
2020	207	1,008	$2,522,151
2021	171	725	$2,899,668
2022	202	840	$3,216,584
2023	254	1,212	$4,635,574
2024	244	999	$3,880,307

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	39	199	$15,555
2016	17	145	$6,534
2017	20	67	$4,127
2018	43	63	$9,223
2019	22	35	$2,870
2020	32	53	$7,916
2021	16	33	$3,264
2022	16	18	$2,369
2023	35	70	$10,184
2024	15	24	$3,216

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	833	1,897	$94
82728	Ferritin (blood protein) level	437	680	$13
80053	Blood test, comprehensive group of blood chemicals	550	1,199	$10
36415	Insertion of needle into vein for collection of blood sample	610	1,509	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	702	1,858	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	27	756	$489,884
Lenvima	Lenvatinib Mesylate	16	480	$396,218
Pomalyst	Pomalidomide	17	476	$380,209
Jakafi	Ruxolitinib Phosphate	16	480	$353,805
Tagrisso	Osimertinib Mesylate	12	360	$205,383

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	15	24	$3,216

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	36	$987	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Gayatri Nimmagadda, M.D.?

Tedicare shows public-source Medicare data for Gayatri Nimmagadda, M.D. (NPI 1770550998), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gayatri Nimmagadda, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Gayatri Nimmagadda, M.D.?

Gayatri Nimmagadda, M.D. is linked to CHESAPEAKE ONCOLOGY HEMATOLOGY ASSOC (billing NPI 1821065079) in the available physician profile data.

Does Gayatri Nimmagadda, M.D. have Open Payments data?

Gayatri Nimmagadda, M.D. has 36 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.